Loading clinical trials...
Loading clinical trials...
A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-Positive and Hormone Receptor-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer
Conditions
Interventions
Pertuzumab
Trastuzumab
+2 more
Locations
82
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Ironwood Cancer TX & Rsch Ctrs
Chandler, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
Comprehensive Blood & CA Ctr; Research
Bakersfield, California, United States
Rocky Mountain Cancer Center - Denver
Denver, Colorado, United States
Norwalk Hospital
Norwalk, Connecticut, United States
Start Date
February 17, 2012
Primary Completion Date
March 17, 2016
Completion Date
November 14, 2019
Last Updated
October 28, 2020
NCT05468034
NCT04541381
NCT03137095
NCT04852887
NCT06393374
NCT07547774
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions